VolitionRx announces receipt of $13M in milestone payments from Heska

In a regulatory filing, VolitionRx (VNRX) said that on December 29, 2023, the company received $13M in milestone payments from Heska Corporation (HSKA), pursuant to the License and Supply Agreement entered into on March 28, 2022, between Belgian Volition SRL, a wholly-owned subsidiary of the company, and Heska. The milestone payments arose from the successful assay transfer of the Nu.Q Vet Cancer Test onto Heska’s Element i+ Immunodiagnostic Analyzer, a point of care platform for use by veterinarians and designated the “Heska Nu.Q Vet Canine Cancer Screen and Monitor” test.